Arca Biopharma (ABIO)
Arca Biopharma Liabilities: 0.602M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ABIO Liabilities Rankings
| Overall | 99th percentile | 15 of 4384 |
| Sector | 99th percentile | 2 of 504 in Healthcare |
| Industry | 99th percentile | 1 of 159 in Biotechnology |
ABIO Liabilities Range, Past 5 Years
| Minimum | 0.602M | Mar 2012 |
| Maximum | 65.97M | Jun 2007 |
| Average | 20.48M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these ABIO related companies
ABIO News
RT@GarethSoloway Good accumulation on $ABIO today ahead of ASCO.Should continue to climb the next two weeks. Bonus would be news if it hit.
about 3 days ago by InTheMoneyStocks
about 3 days ago by InTheMoneyStocks
Good accumulation on $ABIO today ahead of ASCO. Should continue to climb over the next two weeks. Bonus would be news if it hit.
about 3 days ago by GarethSoloway
about 3 days ago by GarethSoloway
Bio amazing. $ROSG truly a run for the ages. Just holding my small bios $ABIO and $ANX. Be interesting to see if ASCO conference pops them.
about 3 days ago by GarethSoloway
about 3 days ago by GarethSoloway
$ABIO inverted hammer candle formed on daily chart - about time for a reversal me thinks.
about 45 days ago by Good2go
about 45 days ago by Good2go
$ABIO filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FEY
about 51 days ago by MarketBrief
about 51 days ago by MarketBrief
Love the jumps/pumps in $ABIO ... it did a 26% jump just the other day ... don't know why, but stock seems way undervalued at below $1
about 59 days ago by scherf_com
about 59 days ago by scherf_com
$ABIO ready to go nice patern on the daily charts + bio's are hot :)
about 90 days ago by kristofdeblock
about 90 days ago by kristofdeblock
$DARA nice micro bio run today. $ABIO still my favorite that has not run yet. Holding some.
about 110 days ago by GarethSoloway
about 110 days ago by GarethSoloway
Watch $ABIO. Sympathy off other bio runners. Starting to rock N roll
about 111 days ago by GarethSoloway
about 111 days ago by GarethSoloway
ARCA biopharma (ABIO) Awarded U.S. Patent for Methods of Treatment with Bucindolol
Dec 30, 8:03AM Street Insider
Dec 30, 8:03AM Street Insider
ARCA biopharma (ABIO) Enters 1.75M Unit Private Placement; Sees $1.5M in New Proceeds
Dec 22, 8:09AM Street Insider
Dec 22, 8:09AM Street Insider
ARCA biopharma Announces Private Placement of $1.75 Million with Institutional Investors
Dec 22, 8:00AM Business Wire
Dec 22, 8:00AM Business Wire
Arca Biopharma (ABIO) shares now up 94% following resumption after second circuit breaker
Nov 16, 12:38PM Street Insider
Nov 16, 12:38PM Street Insider
ARCA biopharma (ABIO) Reports Substanital Improvement in Onset of Atrial Fibrillation Using Gencaro
Nov 16, 11:50AM Street Insider
Nov 16, 11:50AM Street Insider
ARCA Biopharma halted for circuit breaker after spiking on trial results
Nov 16, 11:49AM FlyOnTheWall
Nov 16, 11:49AM FlyOnTheWall
ARCA biopharma Announces Planned Expansion of Gencaro Development to Atrial Fibrillation
May 26, 8:25AM Business Wire
May 26, 8:25AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABIO | 0.69 | +0.14 | +25.45% | 7.259M |
| ABH | 11.83 | +0.00 | +0.00% | 1.149B |
| ABFS | 12.99 | +0.15 | +1.17% | 330.60M |
| ABD | 9.40 | -0.08 | -0.84% | 523.11M |
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ACH | 10.07 | -0.25 | -2.42% | 1.589B |
| ACGL | 38.31 | -0.31 | -0.80% | 5.188B |
| ACG | 8.20 | +0.00 | +0.00% | |
| ACFN | 8.89 | -0.26 | -2.84% | 157.80M |
| ACFCD | 2.18 | +0.33 | +17.84% |
